Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

TSE Tokyo Price Index TOPIX / Technical Analysis

Continue to favor EAFE over EM. As long as the U.S. dollar remains elevated, we believe  developed international (EAFE) will remain in a leadership position relative to EM (MSCI EM). In this report we highlight actionable set ups within Japan, Switzerland and Australia. Within Japanese Sectors, we focus on opportunities within Technology, Financials, Health Care, and Staples. We also highlight attractive setups within European/UK Sectors, including Health Care, Industrials, Staples and Utilities.

Continue to favor EAFE over EM. As long as the U.S. dollar remains elevated, we believe  developed international (EAFE) will remain in a leadership position relative to EM (MSCI EM). In this report we highlight actionable set ups within Japan, Switzerland and Australia. Within Japanese Sectors, we focus on opportunities within Technology, Financials, Health Care, and Staples. We also highlight attractive setups within European/UK Sectors, including Health Care, Industrials, Staples and Utilities.

We remain cautious as the number of bearish-leaning developments continue to pile up. As a result we continue to believe global equities are vulnerable to a breakdown. We recap important technical levels across markets and highlight Actionable Themes within Services, Consumer Staples, and Health Care. We also highlight attractive set ups in H&amp;M Hennes &amp; Mauritz AB Class B (HM.B-SE).

We remain cautious as the number of bearish-leaning developments continue to pile up. As a result we continue to believe global equities are vulnerable to a breakdown. We recap important technical levels across markets and highlight Actionable Themes within Services, Consumer Staples, and Health Care. We also highlight attractive set ups in H&amp;M Hennes &amp; Mauritz AB Class B (HM.B-SE).

Global Equity Strategy: Bearish-Leaning Developments Continue; Europe/UK Holding Above Support.

Frontier and emerging markets (Vietnam)

Dylan Waller

Nomadic Equity

Thematic (Sector/Industry)

Transition from the Irish Stock Exchange to the London Stock ExchangeDragon Capital’s fund <a href="https://www.smartkarma.com/entities/22754" target="_blank" data-smartkarma-citation="entities:22754">Vietnam Enterprise Investments Limited</a>, which currently trades on the Irish Stock Exchange, may trade on the main market of the London Stock Exchange next month.  The company plans to hold an Extraordinary General Meeting on June the 21st to vote on the approval of this transfer, which is expected to potentially take place next month.  The fund currently manages over $850 million, and is most notable for…

Transition from the Irish Stock Exchange to the London Stock ExchangeDragon Capital’s fund Vietnam Enterprise Investments Limited, which currently trades on the Irish Stock Exchange, may trade on the main market of the London Stock Exchange next month.  The company plans to hold an Extraordinary General Meeting on June the 21st to vote on the approval of this transfer, which is expected to potentially take place next month.  The fund currently manages over $850 million, and is most notable for…

Dragon Capital's VEIL Fund: A 3rd London Listing for Vietnam May Emerge Next Month

Index Rebalance and Special Situations, Quiddity Advisors

Afridi Reyal

Index Rebalance and Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The March 2026 index review results for the F100 and F250 indices were announced yesterday after LSE market close.</li>
<li>There will be two index changes for F100 and two separate index changes for F250. </li>
<li>The announced results were in line with our final expectations discussed here (<a href="https://www.smartkarma.com/discussion/243825" target="_blank" rel="noopener">link</a>).  </li>
</ul>


The March 2026 index review results for the F100 and F250 indices were announced yesterday after LSE market close.
There will be two index changes for F100 and two separate index changes for F250. 
The announced results were in line with our final expectations discussed here (link).  


Quiddity F100/F250 Mar26 Results: All Expected ADDs/DELs Correct; One High Impact ADD

Jpmorgan Claverhouse It / Index Rebalance

<ul>
<li>In this insight, we take a look at the potential index changes for the F100 and F250 in the run-up to the March 2026 index rebal event.</li>
<li>We see two M&amp;A-related intra-review changes for the F250 index prior to the March 2026 rebal. Both are likely to happen in the next two weeks.</li>
<li>Our latest estimates suggest there could be no regular changes for the F100 and F250 indexes during the March 2026 rebal which follows.</li>
</ul>


In this insight, we take a look at the potential index changes for the F100 and F250 in the run-up to the March 2026 index rebal event.
We see two M&amp;A-related intra-review changes for the F250 index prior to the March 2026 rebal. Both are likely to happen in the next two weeks.
Our latest estimates suggest there could be no regular changes for the F100 and F250 indexes during the March 2026 rebal which follows.


Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

United Kingdom

Hikma Pharmaceuticals develops, manufactures, and markets a broad range of generic, branded, and in-licensed pharmaceutical products across North America, the Middle East and North Africa (MENA), and Europe. The company specializes in injectables, branded generics, and other non-injectable generic and specialty products for hospitals and retail markets. Hikma Pharmaceuticals was founded in 1978 in Amman, Jordan, and is headquartered in London, UK.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hikma Pharmaceuticals (HIK LN)

Developed Markets Opportunities

Continue to favor EAFE over EM. As long as the U.S. dollar remains elevated, we believe developed international (EAFE) will remain in a leadership...

Vermilion Research

Global Equity Strategy: Bearish-Leaning Developments Continue; Europe/UK Holding Above Support.

We remain cautious as the number of bearish-leaning developments continue to pile up. As a result we continue to believe global equities are...

Vermilion Research

Dragon Capital's VEIL Fund: A 3rd London Listing for Vietnam May Emerge Next Month

Transition from the Irish Stock Exchange to the London Stock ExchangeDragon Capital’s fund Vietnam Enterprise Investments Limited, which currently...

Nomadic Equity

Quiddity F100/F250 Mar26 Results: All Expected ADDs/DELs Correct; One High Impact ADD

March 2026 index review results for F100 and F250 indices were announced in line with expectations. Schiehallion is a big impact name to trade.

Afridi Reyal

Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

We expect Henderson Far East Income (HFEL LN) to be the intra-review F250 replacement for Dowlais (DWL LN). Ashtead Group (AHT LN) is set to be...

Afridi Reyal

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Developed Markets Opportunities

Continue to favor EAFE over EM. As long as the U.S. dollar remains elevated, we believe developed international (EAFE) will remain in a leadership...

Vermilion Research

Global Equity Strategy: Bearish-Leaning Developments Continue; Europe/UK Holding Above Support.

We remain cautious as the number of bearish-leaning developments continue to pile up. As a result we continue to believe global equities are...

Vermilion Research

Dragon Capital's VEIL Fund: A 3rd London Listing for Vietnam May Emerge Next Month

Transition from the Irish Stock Exchange to the London Stock ExchangeDragon Capital’s fund Vietnam Enterprise Investments Limited, which currently...

Nomadic Equity

Quiddity F100/F250 Mar26 Results: All Expected ADDs/DELs Correct; One High Impact ADD

​March 2026 index review results for F100 and F250 indices were announced in line with expectations. Schiehallion is a big impact name to trade.

Afridi Reyal

Quiddity Leaderboard F100/F250 Mar26: Two High-Impact Intra-Review ADDs

We expect Henderson Far East Income (HFEL LN) to be the intra-review F250 replacement for Dowlais (DWL LN). Ashtead Group (AHT LN) is set to be...

Afridi Reyal

March 2026 index review results for F100 and F250 indices were announced in line with expectations. Schiehallion is a big impact name to trade.